Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q1 and also raises the lower end of its earnings and sales guidance for 2018.
Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down
by Zacks Equity Research
Agenus (AGEN) incurs wider-than-expected loss in Q1 and did not report any revenues during the quarter. The company expects to file six investigational new drugs in 2018.
Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View
by Zacks Equity Research
Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.
Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View
by Zacks Equity Research
AMAG incurs wider-than-expected loss in the first quarter of 2018. The company raised 2018 revenue guidance.
Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in the first quarter and also beat revenues. Rolontis successful in phase III study.
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress
by Zacks Equity Research
Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.
Bayer (BAYRY) Misses Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Bayer (BAYRY) misses first-quarter 2018 earnings and sales estimates.
Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.
Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View
by Zacks Equity Research
Zoetis (ZTS) exceeds both earnings and sales expectations in the first quarter of 2018.
Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.
Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong
by Zacks Equity Research
Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.
Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.
Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
by Zacks Equity Research
Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.
Catalyst Enrolls First Patient in Phase III Firdapse Study
by Zacks Equity Research
Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis.
Bayer to Divest 3.6% Stake to Singapore Company Temasek
by Zacks Equity Research
Bayer (BAYRY) will divest its 3.6% stake to Singapore's state investment company Temasek for total gross proceeds of ???3 billion.
U.S. Markets Close Highest in a Month: 4 Momentum Picks
by Nalak Das
Stock market momentum will persist as first-quarter earnings have so far have been better than expected and several big companies are yet to release results.
Alnylam (ALNY) Reports Positive Data for RNAi Candidate
by Zacks Equity Research
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
Alkermes Rallies as FDA Accepts NDA for Depression Drug
by Zacks Equity Research
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Intercept Reports Phase III Sub-Study Liver Biopsy Data
by Zacks Equity Research
Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis.
Here's Why Geron Stock Surged More Than 90% in 6 Months
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Protagonist Therapeutics (PTGX) Enters Oversold Territory
by Zacks Equity Research
Protagonist Therapeutics, Inc. (PTGX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock